Back to top
Search by company, common medicine name, or title of Risk Minimisation Material
For Healthcare Professionals
For Healthcare Professionals
Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.
This risk minimisation material is a condition of the marketing authorisation. It contains important safety information that you need to be aware of before, during and after treatment with ipilimumab. Please ensure that you carry this card with you at all times to inform any healthcare professional treating you (e.g., emergency department personnel) that you are receiving treatment with ipilimumab.
For Healthcare Professionals
This guide is intended to inform HCPs on how to monitor and manage symptoms associated with CRS and serious neurologic adverse reactions/ICANS, and provide guidance on reporting these serious adverse reactions and any adverse reactions associated with the use of either of these two Kite cellular therapy products.
The Healthcare Professionals Guide has been updated to reflect a post-infusion daily monitoring period of 7 days. Further updates were made, including replacing the requirement to stay within 2 hours of the qualified treatment centre, to stay within proximity of a qualified treatment centre for 4 weeks following infusion.
Are you a healthcare professional?
Skip to main content